Anna D. Staniszewska

Stat3 controls lysosomal-mediated cell death in vivo

Peter Kreuzaler, Anna D. Staniszewska, Wenjing Li et al. · Nature Cell Biology · 2011 · 308 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +12

Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer

Chrysiis Michaloglou, Claire Crafter, Oona Delpuech et al. · Molecular Cancer Therapeutics · 2018 · 190 citations · Full text

Life Sciences, Cancer Biology, Oncology +17

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS

Sarah J. Ross, Alexey S. Revenko, Lyndsey Hanson et al. · Science Translational Medicine · 2017 · 182 citations

Medicine, Oncology, Pharmacology +16

Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper

Giuditta Illuzzi, Anna D. Staniszewska, Sonja J. Gill et al. · Clinical Cancer Research · 2022 · 171 citations · Full text

Medicine, Oncology, Pharmacology +13

Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-<i>N</i>-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs

Jeffrey W. Johannes, Amber Balazs, Derek Barratt et al. · Journal of Medicinal Chemistry · 2021 · 140 citations · Full text

Life Sciences, Medicinal Chemistry, Oncology +13